HomeNewsVideos

SCPI to take on PPH devices sales

20 December 2022 10:42

JAKARTA – PT Organon Pharma Indonesia Tbk (SCPI) plans to branch out its business to selling Postpartum Haemorrhage (PPH) medical devices. The decision will be further discussed in the Extraordinary General Shareholders Meeting on January 18, 2023.

According to the information discosure quoted Tuesday (20/12), the Public Appraisal Service Office of Rengganis, Hamid, and Partners, which has been appointed by SCPI, concludes that this plan is viable after analysing the market feasibility, the technical aspects, the business pattern, the management model, and the financial aspects.

As the name suggests, the PPH devices are commonly used to prevent postpartum haemorrhage in labor. Historically, the market share for this particular medical device soared 16.57% to USD 3.36 billion in 2020.

In 2022, the market share is estimated to reach USD 10.5 million, even reaching USD 14.37 million in 2027 with a compound annual growth rate of 6.64%. (LK/ZH)

© 2024 - IDN Financials - All Rights Reserved.